KEGG   DRUG: Mirvetuximab soravtansine
Entry
D10954                      Drug                                   
Name
Mirvetuximab soravtansine (USAN/INN);
Mirvetuximab soravtansine-gynx;
Elahere (TN)
Product
ELAHERE (ImmunoGen)
Class
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Remark
ATC code: L01FX26
Product: D10954<US>
Efficacy
Antineoplastic, Cell growth inhibitor
  Disease
Epithelial ovarian cancer (folate receptor alpha positive) [DS:H00027]
Fallopian tube cancer (folate receptor alpha positive) [DS:H01554]
Primary peritoneal cancer (folate receptor alpha positive) [DS:H01665]
  Type
Antibody-drug conjugate
Target
FOLR1 [HSA:2348] [KO:K13649]
TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]
  Pathway
hsa01523  Antifolate resistance
hsa04144  Endocytosis
Metabolism
Enzyme: CYP3A4 [HSA:1576]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX26 Mirvetuximab soravtansine
      D10954  Mirvetuximab soravtansine (USAN/INN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Mirvetuximab Soravtansine
    D10954  Mirvetuximab soravtansine (USAN/INN)
Drug groups [BR:br08330]
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D10954  Mirvetuximab soravtansine
Target-based classification of drugs [BR:br08310]
 Transporters
  Other transporters
   Others
    FOLR1
     D10954  Mirvetuximab soravtansine (USAN/INN) <US>
 Not elsewhere classified
  Cellular process
   Cytoskeleton
    TUBB
     D10954  Mirvetuximab soravtansine (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10954
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10954
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10954
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D10954
Other DBs
CAS: 1453084-37-1
PubChem: 350078327
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system